Pathwork Diagnostics Inc announced that it has entered into a research collaboration with Novartis.
The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed.
"There is no question that the future of cancer treatment will require and depend on molecular diagnostics," said Richard Klausner, MD, former director of the National Cancer Institute and member of Pathwork Diagnostics Board of Directors. "The collaboration between Pathwork and Novartis has the potential to yield diagnostic products that improve the quality of cancer care worldwide."
Source: Pathwork Diagnostics